We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other health information services stocks.
Health Information Services stocks have become a key focus for investors as AI starts to enter more domains in 2025. Some of the most amazing gains have come in health information services stocks that are utilizing AI to improve research and services in the healthcare sector.
The healthcare information services sector allows investors to gain exposure to a number of growing and emerging technologies including cloud-backed software solutions to physician enablement platforms. Some of the companies in our list are surging based on earnings anticipation while others are increasing in share price because of their upcoming products or revenue growth.
To come up with our list of top 10 health information services stocks outpacing the broader market in 2025, we only considered stocks with a market cap of at least $2 billion that were outperforming the S&P 500 index.
A technician in a lab coat standing in a cleanroom with energy storage systems in the background.
Tempus AI, Inc. (NASDAQ:TEM)
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that provides polymerase chain reaction profiling, molecular genotyping, next-generation sequencing diagnostics, and other anatomic and molecular pathology testing services. The company serves pharmaceutical companies, researchers, healthcare providers, biotechnology companies, and other third parties. The stock is showing a significant uptick gaining over 169% this year.
Tempus AI, Inc. (NASDAQ:TEM) has launched a new xT CDx, an FDA-approved Next-Generation Sequencing in vitro diagnostic device last month which is available to all healthcare professionals across the country. xT CDx offers a detailed view with one of the most comprehensive gene panels available. It examines 648 genes to identify solid tumors and also crucial insight to support treatment decisions for colorectal cancer patients.
Ezra Cohen, MD, CMO of Oncology at Tempus said:
This is consistent with the goal of improving the outcomes for all of their patients, and we look forward to providing xT CDx nationally to make that possible.
In addition to this, the company achieved another milestone with the launch of its AI-based personalized health concierge app known as Olivia. The company generates only a small amount of earnings through its AI apps business. AI applications generated only 1% of the total TEM’s revenue in 2023 and 1.5% in 2024. However, as AI development progresses in 2025, this could become a significant driver of future growth for the company.
Overall TEM ranks 1st on our list of the health information services stocks outpacing the market in 2025. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as TEM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article was originally published at Insider Monkey.
